UTMB researchers create single-dose Ebola vaccine
The vaccine uses vesicular stomatitis virus, a virus that is not harmful to humans, to carry the Ebola virus into the body to provoke an immune response. The team tested the vaccine against the virus in a nonhuman primate model.
"These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks," UTMB professor of Microbiology and Immunology Thomas Geisbert said. "We are excited at the possibility of helping develop a way to stop this deadly disease. We have a lot of more work to accomplish but it's important to note that this is a big step."
As of today, Ebola has killed approximately 10,000 people and become a worldwide health concern.
"It was not known whether any of these vaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea," Profectus Biosciences Chief Scientific Officer for Vaccines John Eldridge said. "Our findings show that our candidate vaccines provided complete, single-dose protection from a lethal amount of the Makona strain of Ebola virus."
More details are available in the latest edition of Nature.